Page 95 - GPD-2-1

Gene & Protein in Disease A pan-cancer analysis of HMGB1

30. Zhang QY, Wu LQ, Zhang T, et al., 2015, Autophagy- https://doi.org/10.1177/1533033820948054
mediated HMGB1 release promotes gastric cancer cell 37. Ren Y, Cao L, Wang L, et al., 2021, Autophagic secretion
survival via RAGE activation of extracellular signal- of HMGB1 from cancer-associated fibroblasts promotes
regulated kinases 1/2. Oncol Rep, 33(4): 1630–1638.
metastatic potential of non-small cell lung cancer cells via
https://doi.org/10.3892/or.2015.3782 NFκB signaling. Cell Death Dis, 12(10): 858.
31. Zhang W, An F, Xia M, et al., 2019, Increased HMGB1 https://doi.org/10.1038/s41419-021-04150-4
expression correlates with higher expression of c-IAP2 38. Jiao D, Zhang J, Chen P, et al., 2021, HN1L promotes
and pERK in colorectal cancer. Medicine (Baltimore), migration and invasion of breast cancer by up-regulating
98(3): e14069. the expression of HMGB1. J Cell Mol Med, 25(1): 397–410.
https://doi.org/10.1097/md.0000000000014069 https://doi.org/10.1111/jcmm.16090
32. Ye L, Zhang Q, Cheng Y, et al., 2018, Tumor-derived 39. He H, Wang X, Chen J, et al., 2019, High-mobility group box
exosomal HMGB1 fosters hepatocellular carcinoma 1 (HMGB1) promotes angiogenesis and tumor migration by
immune evasion by promoting TIM-1(+) regulatory B cell regulating hypoxia-inducible factor 1 (HIF-1α) expression
expansion. J Immunother Cancer, 6(1): 145. via the phosphatidylinositol 3-Kinase (PI3K)/AKT signaling
https://doi.org/10.1186/s40425-018-0451-6 pathway in breast cancer cells. Med Sci Monit, 25: 2352–2360.
33. Zuo Z, Che X, Wang Y, et al., 2014, High mobility https://doi.org/10.12659/msm.915690
group Box-1 inhibits cancer cell motility and metastasis by 40. Liang L, Fu J, Wang S, et al., 2020, MiR-142-3p enhances
suppressing activation of transcription factor CREB and chemosensitivity of breast cancer cells and inhibits
nWASP expression. Oncotarget, 5(17): 7458–7470. autophagy by targeting HMGB1. Acta Pharm Sin B, 10(6):
https://doi.org/10.18632/oncotarget.2150 1036–1046.
34. Hou X, Lin S, Liu Y, et al., 2022, Analysis of the tumor https://doi.org/10.1016/j.apsb.2019.11.009
microenvironment and mutation burden identifies 41. Li P, Xu M, Cai H, et al., 2019, The effect of HMGB1 on
prognostic features in thymic epithelial tumors. Am J Cancer the clinicopathological and prognostic features of cervical
Res, 12(5): 2387–2396. cancer. Biosci Rep, 39(5): BSR20181016.
35. Huang C, Huang Z, Zhao X, et al., 2018, Overexpression https://doi.org/10.1042/bsr20181016
of high mobility group box 1 contributes to progressive
clinicopathological features and poor prognosis of 42. Xu Y, Chen Z, Zhang G, et al., 2015, HMGB1 overexpression
human bladder urothelial carcinoma. Onco Targets Ther, correlates with poor prognosis in early-stage squamous
11: 2111–2120. cervical cancer. Tumour Biol, 36(11): 9039–9047.
https://doi.org/10.1007/s13277-015-3624-7
https://doi.org/10.2147/ott.S155745
43. Liu Y, Xie C, Zhang X, et al., 2010, Elevated expression of
36. Wang XH, Zhang SY, Shi M, et al., 2020, HMGB1 promotes
the proliferation and metastasis of lung cancer by activating HMGB1 in squamous-cell carcinoma of the head and neck
the Wnt/β-catenin pathway. Technol Cancer Res Treat, 19: and its clinical significance. Eur J Cancer, 46(16): 3007–3015.
1533033820948054. https://doi.org/10.1016/j.ejca.2010.07.016

Volume 2 Issue 1 (2023) 13 https://doi.org/10.36922/gpd.301